The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. Their ABBV share price forecasts range from $140.00 to $200.00. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. Build a CFD portfolio with your favourite companies. I am not receiving compensation for it (other than from Seeking Alpha). Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally. All Rights Reserved. First we can take a quick look at what a forward income statement for AbbVie might look like to 2030. How do I arrive at my share price target? The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. Real-time analyst ratings, insider transactions, earnings data, and more. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. That reflects uncertainty about what the future holds for AbbVie. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. If you rely on the information on this page then you do so entirely on your own risk. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. As such, forecasting stock prices is more of an art than a science. Stock Price Forecast The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. AbbVie made the bold decision to take on a heavy debt load and bid for Allergan, with the deal being completed in 2020. If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. Gene therapies have been a long time coming, having first been popularized in the early noughties. Zscaler, Inc Plummets, Is It Time To Buy The Dip? AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. AbbVie has a P/B Ratio of 15.97. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. The difference between trading assets and CFDs. The company reported its first revenue for Botox competitor Daxxify. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. Get short term trading ideas from the MarketBeat Idea Engine. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Earnings for AbbVie are expected to decrease by -0.55% in the coming year, from $11.00 to $10.94 per share. Most stock quote data provided by BATS. The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. ABBV Stock 12 Months Forecast. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Note that analysts ABBV stock forecasts can be wrong. For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. AbbVie has 5 focus areas for its research and products. Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. This would represent an increase of 1.78%. (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. One of the few pain points AbbVie experienced during a year of portfolio wide growth in 2022 was the decline in the revenue contribution from Imbruvica, approved to treat various types of lymphoma. Compare Top Brokerages Here. The companys operations span 20 countries, treating more than 60 million people and 40 conditions annually. AbbVie has a PEG Ratio of 3.51. Net earnings also saw a steep rise to $4.49bn from $3.55bn, while net revenue jumped to $13.54bn from 13.01bn. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. I believe AbbVie is likely 15 - 20% undervalued at current price. I have no business relationship with any company whose stock is mentioned in this article. Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. See what's happening in the market right now with MarketBeat's real-time news feed. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. That certainly won't derail the oncology division however. We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. Discovery Company. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Price target. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. As I have mentioned in previous notes, however, the gains owe more to price hikes than sales volumes, and come 2023 and the LOE, even AbbVie admits the blow to revenues will be substantial. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. The company's average rating score is 2.44, and is based on 7 buy ratings, 9 hold ratings, and no sell ratings. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. CFDs are complex leveraged instruments and come with a high risk of losing money. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. It now expects full-year profit in the range of $13.92-$14.12 a share. Past performance is no guarantee of future results. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. These are mostly related to the US Food and Drug Administrations (FDA) approval of Abbvies drug Rinvoq for ulcerative colitis and positive top-line results from the Phase 3 induction study U-EXCEL. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. PEG Ratios above 1 indicate that a company could be overvalued. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB AbbVie could be the biggest global Pharma by revenue generation in 2028. As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. In the U.S. dermatology segment, where approximately 30% of patients exhibit both skin and joint involvement, Skyrizi is already achieving an in-play patient share of nearly 20%. AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Please. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). Receive regular, detailed analysis focused on biotech and healthcare stocks. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. ABBV currently yields 4.1% and has raised its dividend every year since 2013. (AbbVie data). Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. Over the years, AbbView Inc. has made numerous acquisitions. You should never invest money you cannot afford to lose. What other stocks do shareholders of AbbVie own? In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. Within the oncology division sales of Imbruvica fell 17% year-on-year. About the AbbVie, Inc. stock forecast. (my table and forecasts). AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. (my tables). Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. Let's begin our analysis with the immunology division. According to CEO Gonzalez: Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. AbbVie declared a quarterly dividend on Thursday, February 16th. I have been maintaining a revenue forecasting table for AbbVie's products which I have amended based on Q2'22 and H1'22 results, and the slightly downgraded guidance issued for 2022 - management now expects adjusted earnings per share ("EPS") of $13.78 - $13.98, representing growth of 17% at the midpoint. AbbVie has been working hard to ensure the 2 drugs it has developed to replace Humira - Skyrizi, which inhibits the pro-inflammatory cytokine IL23, and Rinvoq, a Janus Kinase (enzymes involved in immune cell function) inhibitor - are winning approvals and growing sales in Humira's markets. ABBV has several positive factors pushing its price performance. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. Having so much debt in a prevailing inflationary environment is also unattractive. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). Since then, however, the stock price has fallen 18% to its current price of $142.6. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. Only 0.08% of the stock of AbbVie is held by insiders. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. The stock projection varied from the low price target of $135 to the high of $200. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. I wrote this article myself, and it expresses my own opinions. AbbVie stock is one of the most well-known pharmaceutical companies. Rinvoq's progress has been a little more circumspect, but almost as impressive. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. The company has a robust pipeline of new products that are in some stage of clinical trials. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. AbbVie projected sales - immunology (my forecasts and assumptions). Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. Outside of Humira, management does not have to worry about LOEs for any of its other portfolio products before the end of the decade, which is encouraging, however, based on my own projections of how AbbVie will generate its revenues between 2023 and 2030, if management wants to drive a CAGR in the high single digits after 2025, it will need some help from its pipeline - not an area of particular strength for AbbVie. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. AbbVie's stock was trading at $161.61 on January 1st, 2023. I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. I have no business relationship with any company whose stock is mentioned in this article. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. My No. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. AbbVie product revenues by quarter and year since FY20. What intrigues here is the possibility of RGX-314, an anti-VEGF gene therapy that Gonzalez believes "has the potential to be a one-time treatment for wet AMD, diabetic retinopathy and other chronic retinal conditions". As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. In this post I model AbbVie product sales to 2030 - including pipeline assets - and use discounted cash flow analysis to calculate a present day share price target. Forecast target price for 03-06-2023: $ 152.58. All rights reserved. During the same quarter in the prior year, the firm posted $3.31 EPS. If you have an ad-blocker enabled you may be blocked from proceeding. A Warner Bros. For the next eight years, the forecast is for Free Cash Flow to grow by . Capital Com is an execution-only service provider. This suggests a possible upside of 3.8% from the stock's current price. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. The ex-dividend date of this dividend is Thursday, April 13th. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%. Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. AbbVie's Dividend and Valuation. According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. It . I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. All generate blockbuster <$1bn per annum sales - in Stelara's case >$9bn per annum, and in Enbrel's case, >$4.5bn. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. Read the conference call transcript. AbbVie discounted cash flow analysis. Sign in to your free account to enjoy all that MarketBeat has to offer. RHHBY vs. ABBV: Which Stock Is the Better Value Option? Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX). Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. This year is off to a strong start. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. Please disable your ad-blocker and refresh. Please disable your ad-blocker and refresh. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Kateryna Onyshchuk/iStock via Getty Images. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. It should be noted however that, with ~$12bn near-term debt falling due, and long-term debt of ~$61bn - most of it due to the $66bn acquisition of Allergan, completed in 2020, AbbVie has some hefty interest expense payments to make - $15bn between 2022 and 2027, I estimate, and the level of debt makes it tough for the company to invest in M&A deals. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. To summarize, although AbbVie does not have the same clout in oncology as it does in immunology - as evidenced perhaps by the declining sales of Imbruvica - it is clearly an area of focus for management. Within eye care, Restasis was a major disappointment, and the entire division seems to be struggling, with total revenues falling from ~$920m in Q2'21, to ~$720m in Q2'22. The five-year dividend growth rate is just below 18%. The median estimate represents a +5.72% increase from the last price of 156.07. Shares are consolidating with a buy. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. AbbVie Stock Forecast 03-06-2023. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Only you can design whether Abbvie stock is the right investment for you. AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. I'm on twitter @edmundingham.
Oasis Domestic Violence Shelter Owensboro Ky,
Jetblue Pilot Base Seniority,
Digital Newspaper Subscription Pittsford, Ny,
Sheraton Parsippany Events,
Articles A
